Anifrolumab Therapy in Dermatomyositis: New Insights From Refractory Patients
Authors' conclusion
The data we collected showed a significant reduction in CDASI-A values.
Study context
- Population
- Patients with dermatomyositis (DM) with cutaneous involvement refractory to different immunosuppressive treatments50% female, mean age 60 years
- Participants
- 4 patients
- Outcome
- Evolution of skin involvement by CDASI-A
Methodological detailsrefractory patients
- Refractory patients
Main finding
As reported in the abstract
CDASI-A, mean (scale /100)
Observational data: associations, not effects.
Further findings
MMT-8, mean (scale /80)
| Outcome | Enrollment | After treatment |
|---|---|---|
| Daily GC dose (prednisone), mean | mean 10 mg | 4 mg |
| PtGA, mean (scale /10) | mean 7.5 /10 | 1.5 /10 |
Original publication
Anifrolumab Therapy in Dermatomyositis: New Insights From Refractory Patients. J Rheumatol. Published 1 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →